Postpartum Support International: The FDA approval of Zuranolone is a hopeful step forward in managing the mental health needs of new parents experiencing postpartum depression.
Postpartum Support International: The FDA approval of Zuranolone is a hopeful step forward in managing the mental health needs of new parents experiencing postpartum depression.
August 7, 2023 – On Friday, August 4th, the FDA approved a new drug to treat Postpartum Depression, with results being seen as soon as 3 days – much quicker than other prescription medications available on the market today. The new drug Zuranolone, a pill that is taken daily for a 14-day period to treat postpartum depression, would be a lifesaving option for postpartum individuals who need a quick and effective option.
“The FDA’s approval is welcome news for the estimated 500,000 women in the United States who report experiencing symptoms of this devastating and often misunderstood illness each year,” said Wendy N. Davis, Ph.D., PMH-C, Executive Director at Postpartum Support International. “Women with PPD desperately need prompt care and additional treatment options that can provide quick relief so they can be healthy and present during this momentous time in their lives.”
Postpartum Support International is hopeful about the opportunities this new treatment offers, by providing a more accessible, and hopefully effective, treatment option for those in need. At this time the cost of the drug has yet to be released, but in comparison to other options, we hope that this will be more accessible to patients in need, and a treatment plan that non-psychiatric prescribers can use to help their patients. Medication exists alongside support, access to treatment, and social equity. You don’t need a diagnosis to reach out. 800-944-4773 voice or text – we are here for all.
Perinatal Mental Health (PMH) disorders, including Postpartum Depression, are the most frequent complications of childbearing. They are also ranked among the top underlying causes of pregnancy-related deaths in the U.S. Although postpartum depression is commonly cited, other PMH disorders include anxiety, obsessive-compulsive disorder, post-traumatic stress disorder, bipolar disorder, and psychosis. They affect parents of every culture, age, income, gender, and race.
About Postpartum Support International
Founded by a new mother in 1987 to increase awareness among public and professional communities about the emotional difficulties women can experience during and after pregnancy, Postpartum Support International (PSI) offers a wealth of resources for a wide range of needs, situations, and audiences to give families the strongest and healthiest start possible through support and community. PSI offers support, resources, best-practice training and certification for healthcare professionals and volunteer coordinators nationwide and in more than 30 countries. PSI is committed to eliminating stigma and ensuring compassionate and quality care and support are available to all families. Need help? Call 1-800-944-4PPD (4773). Learn more at postpartum.net.
